124 related articles for article (PubMed ID: 16317695)
1. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans.
Hofmann AF; Zakko SF; Lira M; Clerici C; Hagey LR; Lambert KK; Steinbach JH; Schteingart CD; Olinga P; Groothuis GM
Hepatology; 2005 Dec; 42(6):1391-8. PubMed ID: 16317695
[TBL] [Abstract][Full Text] [Related]
2. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
3. Biliary secretion and hepatic metabolism of taurine-conjugated 7 alpha-hydroxy and 7 beta-hydroxy bile acids in the dog. Defective hepatic transport and bile hyposecretion.
Nakagaki M; Danzinger RG; Hofmann AF; DiPietro RA
Gastroenterology; 1984 Sep; 87(3):647-59. PubMed ID: 6745618
[TBL] [Abstract][Full Text] [Related]
4. Effect of side chain length on biotransformation, hepatic transport, and choleretic properties of chenodeoxycholyl homologues in the rodent: studies with dinorchenodeoxycholic acid, norchenodeoxycholic acid, and chenodeoxycholic acid.
Yeh HZ; Schteingart CD; Hagey LR; Ton-Nu HT; Bolder U; Gavrilkina MA; Steinbach JH; Hofmann AF
Hepatology; 1997 Aug; 26(2):374-85. PubMed ID: 9252148
[TBL] [Abstract][Full Text] [Related]
5. Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
Trauner M; Halilbasic E; Claudel T; Steinacher D; Fuchs C; Moustafa T; Pollheimer M; Krones E; Kienbacher C; Traussnigg S; Kazemi-Shirazi L; Munda P; Hofer H; Fickert P; Paumgartner G
Dig Dis; 2015; 33(3):433-9. PubMed ID: 26045280
[TBL] [Abstract][Full Text] [Related]
6. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
Halilbasic E; Fiorotto R; Fickert P; Marschall HU; Moustafa T; Spirli C; Fuchsbichler A; Gumhold J; Silbert D; Zatloukal K; Langner C; Maitra U; Denk H; Hofmann AF; Strazzabosco M; Trauner M
Hepatology; 2009 Jun; 49(6):1972-81. PubMed ID: 19475687
[TBL] [Abstract][Full Text] [Related]
7. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
8. Hypercholeresis induced by unconjugated bile acid infusion correlates with recovery in bile of unconjugated bile acids.
Gurantz D; Schteingart CD; Hagey LR; Steinbach JH; Grotmol T; Hofmann AF
Hepatology; 1991 Mar; 13(3):540-50. PubMed ID: 1999323
[TBL] [Abstract][Full Text] [Related]
9. Active enterohepatic cycling is not required for the choleretic actions of 24-norUrsodeoxycholic acid in mice.
Truong JK; Li J; Li Q; Pachura K; Rao A; Gumber S; Fuchs CD; Feranchak AP; Karpen SJ; Trauner M; Dawson PA
JCI Insight; 2023 Mar; 8(6):. PubMed ID: 36787187
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular bile acid transport and ursodeoxycholic acid hypercholeresis.
Scharschmidt BF; Lake JR
Dig Dis Sci; 1989 Dec; 34(12 Suppl):5S-15S. PubMed ID: 2689116
[TBL] [Abstract][Full Text] [Related]
11. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
Steinacher D; Claudel T; Trauner M
Dig Dis; 2017; 35(3):282-287. PubMed ID: 28249257
[TBL] [Abstract][Full Text] [Related]
13. Bile acids with a cyclopropyl-containing side chain. IV. Physicochemical and biological properties of the four diastereoisomers of 3 alpha,7 beta-dihydroxy-22,23-methylene-5 beta-cholan-24-oic acid.
Roda A; Grigolo B; Aldini R; Simoni P; Pellicciari R; Natalini B; Balducci R
J Lipid Res; 1987 Dec; 28(12):1384-97. PubMed ID: 3430066
[TBL] [Abstract][Full Text] [Related]
14. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Na+/H+ exchange in the rat is associated with decreased ursodeoxycholate hypercholeresis, decreased secretion of unconjugated urodeoxycholate, and increased ursodeoxycholate glucuronidation.
Lake JR; Renner EL; Scharschmidt BF; Cragoe EJ; Hagey LR; Lambert KJ; Gurantz D; Hofmann AF
Gastroenterology; 1988 Aug; 95(2):454-63. PubMed ID: 2455672
[TBL] [Abstract][Full Text] [Related]
16. Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis.
Buko VU; Lukivskaya OY; Naruta EE; Belonovskaya EB; Tauschel HD
J Clin Exp Hepatol; 2014 Dec; 4(4):293-301. PubMed ID: 25755576
[TBL] [Abstract][Full Text] [Related]
17. Biotransformation of topotecan in the isolated perfused rat liver: identification of three novel metabolites.
Platzer P; Schaden S; Thalhammer T; Hamilton G; Rosenberg B; Silgoner I; Jäger W
Anticancer Res; 1998; 18(4A):2695-700. PubMed ID: 9703931
[TBL] [Abstract][Full Text] [Related]
18. Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
Halilbasic E; Steinacher D; Trauner M
Dig Dis; 2017; 35(3):288-292. PubMed ID: 28249255
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
Fickert P; Pollheimer MJ; Silbert D; Moustafa T; Halilbasic E; Krones E; Durchschein F; Thüringer A; Zollner G; Denk H; Trauner M
J Hepatol; 2013 Jun; 58(6):1201-8. PubMed ID: 23369794
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites.
Li W; Zhang D; Wang L; Zhang H; Cheng PT; Zhang D; Everett DW; Humphreys WG
Drug Metab Dispos; 2006 May; 34(5):807-20. PubMed ID: 16467134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
